INSM:NSD-Insmed Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 76.29

Change

-5.26 (-6.45)%

Market Cap

USD 13.70B

Volume

2.51M

Analyst Target

USD 45.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.52 (+0.73%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-13.87 (-1.99%)

USD 76.39B
ARGX argenx NV ADR

-2.06 (-0.33%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

-3.22 (-1.30%)

USD 31.94B
ONC BeiGene, Ltd.

-26.27 (-9.67%)

USD 25.62B
RPRX Royalty Pharma Plc

+0.22 (+0.65%)

USD 18.65B
SMMT Summit Therapeutics PLC

-1.56 (-7.54%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-10.02 (-3.13%)

USD 14.37B
INCY Incyte Corporation

-3.24 (-4.41%)

USD 14.22B
BMRN Biomarin Pharmaceutical Inc

-0.14 (-0.20%)

USD 13.58B

ETFs Containing INSM

LFSC F/m Emerald Life Sciences.. 5.91 % 0.00 %

-1.26 (-5.15%)

USD 0.06B
CURE:AU ETFS S&P Biotech ETF 2.46 % 0.00 %

+1.25 (+-5.15%)

USD 0.04B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.52 % 0.00 %

-176.00 (-5.15%)

USD 2.15B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.52 % 0.00 %

+0.42 (+-5.15%)

USD 2.11B
RSSL Global X Funds 0.51 % 0.00 %

-2.28 (-5.15%)

USD 1.55B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.48 % 0.00 %

-0.37 (-5.15%)

USD 4.81B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.48 % 0.00 %

N/A

USD 4.74B
R2US:SW SPDR® Russell 2000 US Sm.. 0.48 % 0.00 %

-0.04 (-5.15%)

USD 4.92B
ITWO Proshares Russell 2000 Hi.. 0.46 % 0.00 %

-1.10 (-5.15%)

USD 0.05B
XRS2:SW Xtrackers Russell 2000 UC.. 0.44 % 0.00 %

+0.10 (+-5.15%)

USD 2.29B
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

-0.27 (-5.15%)

USD 0.02B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

-5.87 (-5.15%)

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

-9.20 (-5.15%)

N/A
JKJ 0.00 % 0.25 %

N/A

N/A
JKK 0.00 % 0.30 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-8.59 (-5.15%)

USD 0.77B
BTEC 0.00 % 0.42 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

-13.12 (-5.15%)

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

-9.30 (-5.15%)

USD 10.02B
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

-3.59 (-5.15%)

USD 0.41B
UWM ProShares Ultra Russell20.. 0.00 % 0.95 %

-2.14 (-5.15%)

USD 0.43B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.20 %

-6.71 (-5.15%)

USD 1.05B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.15 %

-2.39 (-5.15%)

USD 11.80B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.55 (-5.15%)

USD 5.14B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

-5.30 (-5.15%)

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 2.91B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-2.60 (-5.15%)

N/A
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.56 (-5.15%)

N/A
ISCG iShares Morningstar Small.. 0.00 % 0.00 %

-1.33 (-5.15%)

USD 0.68B
ISCB iShares Morningstar Small.. 0.00 % 0.00 %

-1.39 (-5.15%)

USD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.50% 83% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.50% 83% B 85% B
Trailing 12 Months  
Capital Gain 169.86% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 169.86% 97% N/A 97% N/A
Trailing 5 Years  
Capital Gain 197.20% 94% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 197.20% 94% A 92% A
Average Annual (5 Year Horizon)  
Capital Gain 396.16% 91% A- 96% N/A
Dividend Return 396.16% 91% A- 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 2,019.14% 9% A- 4% F
Risk Adjusted Return 19.62% 77% C+ 52% F
Market Capitalization 13.70B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector